Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

XLO

XLO News

Newswire

09:56

Xilio Therapeutics Reports Q3 Collaboration Revenue Growth

07:33

Xilio Therapeutics Reports Positive Phase 2 Data, Anticipates Cash Runway

04:06

Xilio Therapeutics Presents Phase 2 Vilastobart Combination Data and Identifies High Plasma TMB as Predictive Biomarker in MSS mCRC

16:04

Xilio Therapeutics shares rise 10.63% after-hours after Phase 2 data shows 40% ORR in MSS mCRC with high plasma TMB.

09:16

Xilio Therapeutics' Vilastobart Achieves 40% ORR in MSS mCRC Patients

View More

About XLO

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More